Breast-Adjuvant Trial
The following MCCRC cancer control/prevention clinical trials are currently active. You may click on the trial number to link to a detailed description on PDQ, the National Cancer Institute's Web site for clinical trials.
| PACS08_0610 | PACS 08/0610, Randomized, Open Label, Multicentric Phase III Trial Evaluating the Benefit of a Sequential Regimen Associating FEC100 and Ixabepilone in Adjuvant Treatment of Non-Metastatic, Poor Prognosis Breast Cancer Defined as Triple-Negative Tumor (HER2 Negative-ER Negative-PR Negative) or HER2 Negative and PR Negative Tumor; in Node Positive or Node Negative Patients [TavIx]. |
For more information, please discuss these trials with your physician, contact the Operations Office or contact an MCCRC treating location near you.